文献速递眼底病与葡萄膜炎

玻璃体腔内甲氨蝶呤作为局部或全身皮质类固醇辅助治疗在玻璃体切除术治疗孔源性视网膜脱离合并脉络膜脱离中的作用:一项先导研究

THE ROLE OF INTRAVITREAL METHOTREXATE AS AN ADJUNCT TO LOCAL OR SYSTEMIC CORTICOSTEROIDS IN VITRECTOMY FOR RHEGMATOGENOUS RETINAL DETACHMENT AND CHOROIDAL DETACHMENT: A Pilot Study.
PubMed 文献 · Retina · 2024-01-01

该先导研究比较了合并脉络膜脱离的孔源性视网膜脱离患者行玻璃体切除术时加用或不加用重复玻璃体腔内甲氨蝶呤的解剖与视力结局。共纳入25眼(A组16眼未用甲氨蝶呤,B组9眼加用甲氨蝶呤),B组视网膜复位成功率89%高于A组50%,但差异无统计学意义(P=0.08);B组视力改善幅度显著大于A组(1.6±1.5 vs 1.18±1 logMAR单位,P=0.05)。作者结论认为重复玻璃体腔内甲氨蝶呤可改善结局且无重大安全性问题,但需进一步研究确定最佳剂量和疗程。

要点

  • B组视网膜复位成功率89%,A组50%,差异无统计学意义(P=0.08)。
  • B组视力改善1.6±1.5 logMAR单位,显著大于A组1.18±1 logMAR单位(P=0.05)。
  • 玻璃体腔内甲氨蝶呤未观察到显著安全性问题。

核心结论

  • 玻璃体切除术后重复玻璃体腔内甲氨蝶呤可改善孔源性视网膜脱离合并脉络膜脱离的结局,且无重大安全性问题。
  • 作者认为仍需进一步研究以确定玻璃体腔内甲氨蝶呤的最佳剂量和疗程,从而有效预防复发。

研究设计与样本

  • 先导研究,比较行玻璃体切除术联合(B组)或不联合(A组)重复玻璃体腔内甲氨蝶呤的孔源性视网膜脱离合并脉络膜脱离眼的解剖与视力结局。
  • 共纳入25例患者的25眼,其中A组16眼、B组9眼,两组基线特征相似。

主要发现

  • A组视网膜复位成功率为50%,B组为89%,差异无统计学意义(P=0.08)。
  • B组从基线至末次随访的视力变化为1.6±1.5 logMAR单位,A组为1.18±1 logMAR单位,B组显著大于A组(P=0.05)。
  • 使用玻璃体腔内甲氨蝶呤未观察到显著安全性问题。

局限性

  • 作者认为仍需进一步研究以确定玻璃体腔内甲氨蝶呤的最佳剂量和疗程,从而有效预防复发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the role of repeated intravitreal methotrexate as an adjunct to pars plana vitrectomy in the management of rhegmatogenous retinal detachment with choroidal detachment. METHOD: The authors compared anatomical and visual outcomes of rhegmatogenous retinal detachment with choroidal detachment eyes that underwent pars plana vitrectomy with (Group B) or without repeated intravitreal methotrexate (Group A). RESULTS: The study included 25 eyes of 25 patients, 16 eyes in Group A and nine in Group B. Both groups had similar baseline characteristics. In Group A, successful retinal attachment was achieved in 50% as compared with 89% in Group B; however, the difference was not statistically significant ( P = 0.08). Also, Group B had a significantly greater change in visual acuity from baseline to the last follow-up visit (1.6 + 1.5 logMAR units) compared with Group A (1.18 + 1 logMAR units) ( P = 0.05). There were no significant safety concerns with the use of intravitreal methotrexate. CONCLUSION: Repeated intravitreal methotrexate after vitrectomy for rhegmatogenous retinal detachment with choroidal detachment improves outcomes without posing major safety concerns. Nonetheless, further investigation is necessary to establish the optimal intravitreal methotrexate dosage and duration to prevent recurrence effectively.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Chahar A, Sen A, Shukla D, et al. THE ROLE OF INTRAVITREAL METHOTREXATE AS AN ADJUNCT TO LOCAL OR SYSTEMIC CORTICOSTEROIDS IN VITRECTOMY FOR RHEGMATOGENOUS RETINAL DETACHMENT AND CHOROIDAL DETACHMENT: A Pilot Study. Retina. 2024. PMID: 38194672. doi:10.1097/IAE.0000000000004046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。